These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 4828634)

  • 1. [Monstrous tumourous changes of the facial bones in secondary hyperparathyroidism (author's transl)].
    Pfeifle J; Koch H; Grabensee B; Knieriem HI
    Dtsch Med Wochenschr; 1974 Mar; 99(9):389-91. PubMed ID: 4828634
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 3. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiology and treatment of renal osteodystrophy].
    Ionova D
    Vutr Boles; 1985; 24(6):23-9. PubMed ID: 3913143
    [No Abstract]   [Full Text] [Related]  

  • 5. [Parathormone as a uremic toxin. Physiopathological bases and general therapeutic guidelines].
    Brancaccio D; Galmozzi C; Pizzocaro G
    Minerva Med; 1985 Mar; 76(9-10):377-82. PubMed ID: 3982693
    [No Abstract]   [Full Text] [Related]  

  • 6. [The course of osteodystrophy in patients with chronic kidney failure on hemodialysis].
    Zemchenko AIu; Shostka GD
    Urol Nefrol (Mosk); 1993; (6):51-4. PubMed ID: 8160326
    [No Abstract]   [Full Text] [Related]  

  • 7. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
    Ishii H; Wada M; Furuya Y; Nagano N; Nemeth EF; Fox J
    Bone; 2000 Feb; 26(2):175-82. PubMed ID: 10678413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary hyperparathyroidism in chronic renal failure.
    Wills MR; Savory J
    Ann Clin Lab Sci; 1981; 11(3):252-61. PubMed ID: 6264838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anomalies of phosphorus-calcium metabolism in renal insufficiency. Value of the physiopathological diagnosis and therapy].
    Hioco D; Dorfmann H; Chot ST; Bordier P; de Zèze S
    Rev Rhum Mal Osteoartic; 1972 Oct; 39(10):617-25. PubMed ID: 5083698
    [No Abstract]   [Full Text] [Related]  

  • 10. [Renal osteodystrophy: role of vitamin D and parathyroid hormone].
    Drüeke T; Ulmann A
    Nouv Presse Med; 1979 May; 8(23):1901-3. PubMed ID: 223122
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic arthralgia in a 46-year-old patient with renal failure].
    Schiller B; Hillebrand G; Bartl R; Linke RP
    Internist (Berl); 1992 Feb; 33(2):117-21. PubMed ID: 1568827
    [No Abstract]   [Full Text] [Related]  

  • 12. Divalent ions in renal failure. Introduction.
    Massry SG
    Kidney Int; 1973 Aug; 4(2):71-2. PubMed ID: 4790867
    [No Abstract]   [Full Text] [Related]  

  • 13. Progressive renal osteodystrophy.
    Peacock E
    ANNA J; 1988 Dec; 15(6):360, 370. PubMed ID: 3214203
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperparathyroidism in chronic renal failure. Assessment of autonomy by plasma-parathyroid-hormone response to alterations in calcium.
    Buckle RM
    Lancet; 1970 Aug; 2(7666):234-7. PubMed ID: 4193689
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis of uremic osteodystrophy.
    Agus ZS; Goldberg M
    Radiol Clin North Am; 1972 Dec; 10(3):545-56. PubMed ID: 4566892
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes.
    Hörl WH
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V2-8. PubMed ID: 15284353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 18. Parathyroid dysfunction end stage renal disease.
    DiTella PJ; Lang GR
    Otolaryngol Clin North Am; 1980 Feb; 13(1):193-201. PubMed ID: 7367004
    [No Abstract]   [Full Text] [Related]  

  • 19. Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy.
    Maschio G; Tessitore N; D'Angelo A; Bonucci E; Lupo A; Valvo E; Loschiavo C; Fabris A; Morachiello P; Previato G; Fiaschi E
    Am J Clin Nutr; 1980 Jul; 33(7):1546-54. PubMed ID: 7395775
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperparathyroidism in the maintenance dialysis patient.
    Glassford DM; Remmers AR; Sarles HE; Lindley JD; Scurry MT; Fish JC
    Surg Gynecol Obstet; 1976 Mar; 142(3):328-32. PubMed ID: 1251311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.